<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In a Danish bi-regional registry-based study, we conducted an analysis of the incidence and clinical importance of secondary <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mpath ids='MPATH_342'>myeloid leukaemia</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>In a total of 630 cases of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, we found 157 (25%) cases of <z:e sem="disease" ids="C0280449" disease_type="Neoplastic Process" abbrv="">secondary AML</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>The secondary <z:mpath ids='MPATH_336'>leukaemia</z:mpath> arose from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (<z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo>) in 77 cases (49%), <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMPD</z:e> (<z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0005547'>myeloproliferative disorder</z:hpo>) in 43 cases (27%) and was therapy-related <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> (t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) in 37 cases (24%) </plain></SENT>
<SENT sid="3" pm="."><plain>Median age at diagnosis of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> was 69 yr in secondary cases when compared to 66 yr in de novo cases (P = 0.006) </plain></SENT>
<SENT sid="4" pm="."><plain>In univariate analyses, <z:e sem="disease" ids="C0280449" disease_type="Neoplastic Process" abbrv="">secondary AML</z:e> was associated with an inferior complete remission (CR) rate (P = 0.008) and poorer overall survival (OS, P = 0.003) whereas in complete remitters, disease-free survival (DFS) of secondary cases was equal to that of de novo cases </plain></SENT>
<SENT sid="5" pm="."><plain>Interestingly, in <z:hpo ids='HP_0000001'>all</z:hpo> further analyses of CR-rates, OS and DFS, when correcting for the influence of age, cytogenetic abnormalities, performance status and leucocyte count (WBC), presence of <z:e sem="disease" ids="C0280449" disease_type="Neoplastic Process" abbrv="">secondary AML</z:e> completely lost prognostic significance </plain></SENT>
<SENT sid="6" pm="."><plain>We conclude that the presence of <z:e sem="disease" ids="C0280449" disease_type="Neoplastic Process" abbrv="">secondary AML</z:e> does not per se convey an unfavourable prognosis and that patients with <z:e sem="disease" ids="C0280449" disease_type="Neoplastic Process" abbrv="">secondary AML</z:e> should be offered the chance of benefiting from treatment according to current frontline <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> protocols </plain></SENT>
</text></document>